Posts

Exelixis Announces U.S. FDA Approval of Cabometyx (cabo...

May 12, 2025 0

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 26, 2025-- Exelixis, Inc. (Nasdaq: EXEL) ...

FDA Approves Vykat XR (diazoxide choline) to Treat Hype...

May 12, 2025 0

REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, In...

Rinvoq (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

Rinvoq (upadacitinib) Receives U.S. FDA Approval for Gi...

May 12, 2025 0

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today an...

FDA Approves Zevaskyn (prademagene zamikeracel) Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa

FDA Approves Zevaskyn (prademagene zamikeracel) Gene Th...

May 12, 2025 0

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ...

FDA Approves Penpulimab-kcqx for the Treatment of Advanced Nasopharyngeal Carcinoma

FDA Approves Penpulimab-kcqx for the Treatment of Advan...

May 12, 2025 0

HONG KONG, April 24, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is...

Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Dupixent (dupilumab) Approved in the U.S. as the First ...

May 12, 2025 0

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmace...

U.S. Food and Drug Administration Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

U.S. Food and Drug Administration Updates Camzyos (mava...

May 12, 2025 0

PRINCETON, N.J.-- April 17, 2025 -- (BUSINESS WIRE)-- Bristol Myers Squibb (NYS...

FDA Approves Mezofy (aripiprazole) Oral Film for the Treatment of Schizophrenia

FDA Approves Mezofy (aripiprazole) Oral Film for the Tr...

May 12, 2025 0

Seoul, Korea -- April 16, 2025 -- CMG Pharmaceuticals, an affiliate of Cha Biote...

FDA Grants Isturisa (osilodrostat) Expanded Indication ...

May 12, 2025 0

Milan, Italy and Bridgewater, NJ, April 16, 2025 – Today Recordati announced tha...

Neurelis Announces FDA Approval for Immediate Use Seizu...

May 12, 2025 0

San Diego, CA – April, 16, 2025 – Neurelis, Inc., today announced that the U.S. ...

Mirum’s Livmarli Now FDA Approved in Tablet Formulation

May 12, 2025 0

FOSTER CITY, Calif.--(BUSINESS WIRE) April 14, 2025 -- Mirum Pharmaceuticals, I...

FDA Grants Interchangeable Designation to Yuflyma (adal...

May 12, 2025 0

INCHEON, South Korea, April 14, 2025 /-- Celltrion, Inc. today announced that th...

FDA Warns Patients and Health Care Professionals Not to Use Compounded Drugs from Fullerton Wellness

FDA Warns Patients and Health Care Professionals Not to...

May 12, 2025 0

Audience: Patients, Health Care Professionals November 1, 2024 -- FDA is warning...

Do Not Purchase or Use Skin-Cap Aerosol Spray Products Because They May Be Harmful to Your Health

Do Not Purchase or Use Skin-Cap Aerosol Spray Products ...

May 12, 2025 0

Audience: Consumers October 30, 2024 -- FDA is warning consumers to not purchase...

Public Safety Notification on Amniotic Fluid Eyedrops

Public Safety Notification on Amniotic Fluid Eyedrops

May 12, 2025 0

Audience: Patients, Health Care Practitioners October 17, 2024 Update: In August...

Staska Pharmaceuticals, Inc. Issues Recall of Ascorbic Acid Solution for Injection (Preservative Free, Non-Corn) 500mg/mL Due to the Presence of Glass Particles

Staska Pharmaceuticals, Inc. Issues Recall of Ascorbic ...

May 12, 2025 0

Audience: Healthcare Provider, Pharmacy October 16, 2024 -- Bennet, NE -- STASKA...

FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize

FDA Clarifies Policies for Compounders as National GLP-...

May 12, 2025 0

Audience: Industry October 2, 2024 -- The U.S. Food and Drug Administration has ...

FDA is Alerting Patients and Health Care Professionals About the Voluntary Withdrawal of Oxbryta from the Market Due to Safety Concerns

FDA is Alerting Patients and Health Care Professionals ...

May 12, 2025 0

Audience: Health Care Professionals, Patients September 26, 2024 -- FDA is alert...

Gilead Issues Voluntary Nationwide Recall of One Lot of Veklury (Remdesivir) for Injection 100 mg/vial Due to the Presence of a Glass Particle

Gilead Issues Voluntary Nationwide Recall of One Lot of...

May 12, 2025 0

Audience: Healthcare Provider, Pharmacy Foster City, Calif., September 20, 2024 ...

FDA Approves Imaavy (nipocalimab-aahu) for the Treatment of Generalized Myasthenia Gravis (gMG)

FDA Approves Imaavy (nipocalimab-aahu) for the Treatmen...

May 12, 2025 0

SPRING HOUSE, Pa., (April 30, 2025) – Johnson & Johnson (NYSE: JNJ) today announ...

FDA Approves Atzumi (dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

FDA Approves Atzumi (dihydroergotamine) Nasal Powder fo...

May 12, 2025 0

DURHAM, N.C., April 30, 2025 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a la...

Shoppers-Plaza Issues Voluntary Nationwide Recall of Fouzee Sugarlin Herbal Formula Due To Presence Of Undeclared Metformin And Glyburide

Shoppers-Plaza Issues Voluntary Nationwide Recall of Fo...

May 12, 2025 0

Audience: Consumer December 16, 2024 – Los Angeles, California - Shoppers-Plaza ...

FDA Adds Boxed Warning to Veozah (fezolinetant) to Highlight the Known Risk of Rare But Serious Liver Injury

FDA Adds Boxed Warning to Veozah (fezolinetant) to High...

May 12, 2025 0

Audience: Patient, Health Professional, OBGYN, Endocrinology Update: December 16...

Drug Safety Communication: Ocaliva (obeticholic acid) - Serious Liver Injury Being Observed in Patients without Cirrhosis

Drug Safety Communication: Ocaliva (obeticholic acid) -...

May 12, 2025 0

Audience: Gastroenterology, Hepatology, Patient, Health Care Professional, Pharm...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.